Live Earnings Conference Call: Neurocrine Biosciences will host a live Q1 2025 earnings call on May 5, 2025 at 4:30PM ET. Follow this link to get details and listen to Neurocrine Biosciences' Q1 2025 earnings call when it goes live. Get details. NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $109.94 +0.26 (+0.23%) As of 10:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Neurocrine Biosciences Stock (NASDAQ:NBIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$108.35▼$110.3350-Day Range$87.54▼$118.7252-Week Range$84.23▼$157.98Volume152,083 shsAverage Volume1.07 million shsMarket Capitalization$10.88 billionP/E Ratio33.35Dividend YieldN/APrice Target$160.90Consensus RatingModerate Buy Company OverviewNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More… Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreNBIX MarketRank™: Neurocrine Biosciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 30th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth51.17% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 33.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 33.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.77. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.58% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Sustainability and ESG2.9 / 5Environmental Score-2.61 Percentage of Shares Shorted4.58% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.78 News SentimentNeurocrine Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Neurocrine Biosciences this week, compared to 15 articles on an average week.Search Interest7 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,629,982.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive DyskinesiaMay 5 at 8:30 AM | prnewswire.comNeurocrine Biosciences (NBIX) Prepares for Q1 Earnings AnnouncementMay 4 at 6:14 PM | gurufocus.comI’ve never sent an email like this but…Today’s email is going to be a little different from EVERY other email you’ve received from me this year. And that’s because Alpha Zone Pro is getting all the credit it deserves – and rightfully so! I mean, how many times do you come across a platform so straightforward that it spots the S&Ps likely move in minutes… And gives you the chance to place a simple trade for a shot at what could be a 79% return as it did for Thomas… All within 60 minutes or less! Don’t get me wrong, there were smaller wins and those that did not work out and there’s always risks when it comes to trading… so I’m definitely not implying that Alpha Zone Pro is 100% perfect. But if top regular traders like Shawn, Thomas & Scott are already crushing it… I don’t see anything stopping you from attempting the same feat starting today.May 5, 2025 | WealthPress (Ad)Neurocrine Biosciences (NBIX) Prepares for Q1 Earnings AnnouncementMay 4 at 6:14 PM | gurufocus.comNeurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on MondayMay 3 at 2:42 AM | americanbankingnews.comWhat to Expect from Neurocrine Biosciences's EarningsMay 2 at 7:46 PM | benzinga.comNeurocrine begins Phase III programme for schizophrenia treatmentMay 2 at 8:23 AM | msn.comNxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with SchizophreniaApril 30, 2025 | globenewswire.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $136.50 at the beginning of 2025. Since then, NBIX stock has decreased by 19.6% and is now trading at $109.68. View the best growth stocks for 2025 here. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Thursday, February, 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by $0.62. Neurocrine Biosciences had a net margin of 14.49% and a trailing twelve-month return on equity of 13.38%. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' Board of Directors initiated a stock buyback program on Friday, February 21st 2025, which authorizes the company to repurchase $500,000,000 in shares, according to EventVestor. This means that the company could purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its stock is undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional shareholders include Brown Advisory Inc. (0.91%), Bank of New York Mellon Corp (0.84%), Jennison Associates LLC (0.81%) and Assenagon Asset Management S.A. (0.39%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Malcolm Lloyd-Smith, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings2/06/2025Today5/04/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$160.90 High Stock Price Target$219.00 Low Stock Price Target$114.00 Potential Upside/Downside+46.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$3.29 Trailing P/E Ratio33.34 Forward P/E Ratio25.63 P/E Growth0.77Net Income$341.30 million Net Margins14.49% Pretax Margin20.63% Return on Equity13.38% Return on Assets9.73% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.28 Sales & Book Value Annual Sales$2.36 billion Price / Sales4.61 Cash Flow$3.19 per share Price / Cash Flow34.35 Book Value$25.97 per share Price / Book4.22Miscellaneous Outstanding Shares98,938,000Free Float95,417,000Market Cap$10.85 billion OptionableOptionable Beta0.33 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NBIX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.